Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3855902 | 0.71 | ALDH1A1 (0.45) | ALDH1A1GAAKMT2ATDP1KDM4E | |
| SCHEMBL2995499 | 0.71 | ALDH1A1 (0.53) | ALDH1A1GAAKMT2ATDP1IDO1 | |
| Hydrochloric Acid SCHEMBL2986141 | 0.69 | ALDH1A1 (0.51) | ALDH1A1GAAKMT2ATDP1IDO1 | |
| SCHEMBL6024162 | 0.67 | SRC (0.36) | ALDH1A1GAAKMT2ATDP1KDM4E | |
| SCHEMBL5766973 | 0.64 | NPC1 (0.49) | ALDH1A1GAANOTUMKDM4EDHODH | |
| SCHEMBL1461839 | 0.64 | MAPT (0.56) | ALDH1A1GAAKMT2ATDP1IDO1 | |
| SCHEMBL11995114 | 0.63 | SIGMAR1 (0.39) | ALDH1A1GAASMN1; SMN2MITFKMT2A | |
| SCHEMBL16470193 | 0.63 | ALDH1A1 (0.50) | ALDH1A1GAAKMT2ATDP1KDM4E | |
| SCHEMBL16470043 | 0.61 | HSD17B10 (0.42) | ALDH1A1SMN1; SMN2KMT2ANOTUMKDM4E | |
| SCHEMBL28040696 | 0.61 | COMT (0.39) | ALDH1A1GAASMN1; SMN2KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1353908-B1 | PROCESSES AND SYNTHETIC INTERMEDIATES FOR PREPARING N-ARYLACRIDANCARBOXYLIC ACID DERIVATIVES | LUMIGEN INC (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1353908-A4 | PROCESSES AND SYNTHETIC INTERMEDIATES FOR PREPARING N-ARYLACRIDANCARBOXYLIC ACID DERIVATIVES | LUMIGEN INC (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1353908-A1 | PROCESSES AND SYNTHETIC INTERMEDIATES FOR PREPARING N-ARYLACRIDANCARBOXYLIC ACID DERIVATIVES | LUMIGEN, INC. (US) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002059096-A1 | PROCESSES AND SYNTHETIC INTERMEDIATES FOR PREPARING N-ARYLACRIDANCARBOXYLIC ACID DERIVATIVES | LUMIGEN, INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| US-6410732-B2 | FORMATION OF BOND BETWEEN NITROGEN ATOM OF ACRIDAN RING AND CARBON ATOM OF ANOTHER AROMATIC OR HETEROAROMATIC RING COMPOUND; ASSAYS FOR PEROXIDASE ENZYMES AND ENZYME INHIBITORS AND IN ASSAYS EMPLOYING ENZYME-LABELED SPECIFIC BINDING PAIRS | LUMIGEN, INC. | 2002-06-25 | — | — | US | disclosed |
| US-20010031869-A1 | Processes and synthetic intermediates for preparing N-arylacridancarboxylic acid derivatives | LUMIGEN, INC. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031869-A1 | Processes and synthetic intermediates for preparing N-arylacridancarboxylic acid derivatives | ALDH3A1, AADAC, SPR | ALDH1A1 64/4885GAA 549/4885SMN1; SMN2 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.